StockNews.com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NAVB opened at $0.00 on Thursday. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve […]

Leave a Reply

Your email address will not be published.

Previous post Spotify Technology (SPOT) to Release Quarterly Earnings on Tuesday
Next post Ethereum Classic Reaches 1-Day Volume of $159.29 Million (ETC)